Dexcom Inc (DXCM) Files Form 4 Insider Selling : Andrew K Balo Sells 5,000 Shares

Dexcom Inc (DXCM): Andrew K Balo , EVP, Clinical and Regulatory of Dexcom Inc sold 5,000 shares on Sep 21, 2016. The Insider selling transaction was reported by the company on Sep 22, 2016 to the Securities and Exchange Commission. The shares were sold at $92.87 per share for a total value of $464,366.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 16, 2016, Kevin R Sayer (President & CEO) sold 7,000 shares at $91.79 per share price.On Sep 14, 2016, Jay S Skyler (director) sold 10,000 shares at $93.00 per share price.Also, On Sep 14, 2016, Barbara Kahn (director) sold 12,500 shares at $61.51 per share price.On Sep 13, 2016, John Lister (General Manager, EMEA) sold 3,560 shares at $93.65 per share price.

Shares of DexCom (DXCM) ended Tuesday, Sep 21, 2016 session in red amid volatile trading. The shares closed down -0.31 points or -0.33% at $92.75 with 7,31,044 shares getting traded. Post opening the session at $93.17, the shares hit an intraday low of $92.1 and an intraday high of $93.495 and the price vacillated in this range throughout the day. The company has a market cap of $7,780 M and the number of outstanding shares has been calculated to be 8,38,83,617 shares. The 52-week high of DexCom is $101.6 and the 52-week low is $47.92.

DexCom Money Flow Index Chart

Company has been under the radar of several Street Analysts.DexCom is Reiterated by The Benchmark Company to Buy and the brokerage firm has raised the Price Target to $ 106 from a previous price target of $86 .The Rating was issued on Aug 3, 2016.

Dexcom Inc. (Dexcom) is a medical device company. The Company is focused on the design development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products consist of DexCom G4 DexCom G4 PLATINUM and DexCom Share System. The DexCom G4 PLATINUM with Share uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone to transmit glucose information to applications on the mobile devices of up to five designated recipients or followers who can remotely monitor a patient’s glucose information and receive alert notifications anywhere they have an Internet connection. SweetSpot’s data transfer service is a Medical Device Data System (MDDS) and allows researchers to control the transfer of data from certain diabetes devices to research tools and databases according to their own research workflows.

Leave a Reply

DexCom - Is it time to Sell?

Top Brokerage Firms are advising their investors on DexCom. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.